An alternative solution for patient with high risk of coronary obstruction underwent TAVI procedure using a novel second-generation device – a case series

Hong Qian 1, Yucheng Chen 2, Zhaoyun Cheng 3 and Yingqiang Guo 1*

Abstract

Background: Obstruction of the left or right coronary artery is a rare but lethal complication during transcatheter aortic valve implantation (TAVI). The new J-Valve™ prosthesis is a new second generation TAVI device which has several features to avoid the coronary obstruction such as low profile design and clip fixation of the native leaflets. The aim of this study is to report our initial experience of using this valve in treating patient with high risk factors for coronary obstruction during TAVI procedure.

Case presentation: Three high surgical risk patients (All females with 77, 76, and 75 years old) with symptomatic aortic stenosis were enrolled. All patients have the common feature of low coronary ostium height (< 10 mm) with narrowed aortic sinus (< 30 mm) on CT angiogram and marked leaflet calcification. Three 25 mm J-Valve prostheses were successfully implanted through trans-apical approach. No coronary obstruction was noted for these patients. Effective aortic open area was significantly increased after valve implantation (Preoperative 0.7, 0.7 and 0.65 cm² – Postoperative 1.8, 1.9 and 2.0 cm²). Only one patient was noted to have trivial degree paravalvular leakage.

Conclusion: The new J-Valve prosthesis is a new second generation TAVI device. This system may provide another safety treatment option for patient with high risk factor for coronary obstruction underwent TAVI procedure.

Keywords: Transcatheter aortic valve implantation, Coronary obstruction

Background

Transcatheter aortic valve implantation (TAVI) has evolved as a routine procedure to treat selected high-risk patients with severe aortic stenosis. Although obstruction of the left or right coronary ostium is a relatively rare but lethal complication during TAVI procedure, it is generally accepted that a distance between the coronary ostium and the annulus less than 10 mm or sinus of Valsalva diameter below 30 mm, and existing of bulky calcified leaflet are risks for coronary occlusion as for several type of classic TAVI devices such as Edward SAPIEN and Medtronic CoreValve [1, 2]. The J-Valve™ system is a brand new second-generation TAVI device featured by three U-shape anatomically oriented devices “claspers” which could facilitate intuitive “self-positioning” valve implantation [3]. Due to the ability of embracing the native calcified leaflets during valve implantation and specially designed bear area on valve stent, this low-profile designed valve is especially suitable for patient who is at high risk for coronary obstruction. We then reported our initial experience of using J-Valve in treating patient with high risk factor for coronary obstruction during TAVI procedure.

Case presentation

Three high surgical risk patients with symptomatic aortic stenosis who are at high risk for coronary occlusion during TAVI procedure were enrolled (three female patients). The basic characters shown in Table 1. These
three patients have the common feature of low coronary ostium height (< 10 mm) with narrowed aortic sinus (< 30 mm). The effective aortic valve opening area (EOA) was 0.7 cm\(^2\), 0.7 cm\(^2\) and 0.65 cm\(^2\) in each patient with marked leaflet calcification. Aortic valve annular size was 24 mm, 25 mm, 24 mm on CT image.

The TAVI procedure using J-Valve™ prosthesis was performed through trans-apical approach (Fig. 1). The procedure detail is described previously [3]. Briefly the apical puncture was done with a super-stiff guide-wire placed into the descending aorta. A 14F sheath was carefully introduced into the left ventricle followed by a balloon catheter. Pre-procedural balloon-valvuloplasty of the native valve was performed under rapid pacing. In parallel, a J-Valve™ prosthesis was crimped into the 27-F Ausper-AS delivery system (Three 25 mm prostheses were used). The delivery system was bluntly inserted into the left ventricle and advanced under fluoroscopic guidance into a supra-annular position. Three ‘U-shaped’ graspers were then completely released first and carefully placed into the corresponding aortic sinus by gently pulling back the delivery system, thereby embracing the native leaflets. The angiogram was then performed to confirm that all the graspers were positioned correctly into the each aortic sinus. The valve was retrieved back gently into the annular plan with the guidance of the graspers and deployed without rapid ventricular pacing. After wound closure, the patient was transferred to the intensive care unit. Further postoperative course was uneventful. At discharge, TTE revealed an excellent valve function with EOA (1.8 cm\(^2\), 1.9 cm\(^2\), 2.0 cm\(^2\) in each patient) without any relevant incompetence. One patient was noted to have trivial degree paravalvular leakage.

**Discussion**

Although the incidence of coronary obstruction revealed in large TAVI series and registries are relatively low, it is still the most lethal complication of TAVI procedure [1]. Evidences have shown that a distance between the coronary ostium and the annulus less than 10 mm or

### Table 1 Basic character of three patients

| Patient | Log-Euroscore (%) | Aortic Valve | Calcification | LCH (mm) | RCH (mm) | Aortic Sinus (mm) | Annular Size (mm) | Valve Size |
|---------|-------------------|--------------|---------------|----------|----------|-------------------|-------------------|------------|
| No1 77y Female | 21% | Severe AS | Moderate | 7.8 | 7.8 | 27 | 24 | 25 |
| No2 76y Female | 20% | Severe AS | Severe | 8.9 | 9.5 | 29 | 25 | 25 |
| No3 75y Female | 22% | Severe AS | Bulky | 8.2 | 7.9 | 27 | 24 | 25 |

LCH Left coronary ostium height, RCH Right coronary ostium height.

---

**Fig. 1** J-Valve implantation in a patient with high risk of coronary obstruction. Upper Panel: Note both left and right coronary height was all less than 10 mm with narrow aortic sinus (a-d). Lower Panel: Angiogram also revealed low coronary ostium height (e). Valve deployment process (f-h): Three Clasper were released and pushed back gently into the aortic sinuses, the valve was retrieved into the annular plan with the help of the locking device. The valve was then deployed without rapid ventricular pacing, further angiogram confirmed good position of the valve while without obvious paravalvular leakage.
sinus of Valsalva diameter below 30 mm, and existing of bulky calcified leaflet are risks for coronary occlusion as for classic TAVI device such as Edward SAPIEN and Medtronic CoreValve due to their design [2]. Contrast to western population, Asian patients always associated with low body weight, relatively small aortic root and low coronary orifice height. In some specific situation, choose of the classic TAVI device may warrant caution or even contraindicated.

The J-Valve™ system is a new second-generation self-expendable low-profile prosthesis that is featured by three U-shape anatomical orientated devices — “Clasper” encircling around the valve frame. The design concept of this device is to facilitate intuitive ‘self-positioning’ valve implantation through embracing the native aortic valve leaflet. In this case serious, successful TAVI procedure was done using this unique system in all three patients who are at high risk for coronary obstruction with low coronary height and narrowed aortic sinus. This valve have several unique features to minimized the risk coronary obstruction including: 1) More accurate position of the device with anatomical orientated devices to avoid malposition; 2) Low-profile design with extra bare mental area in coronary orifice region (Fig. 2); 3) Unlike the traditional design of classic stent valve system, the unique designed U-shape claspers could embrace the native aortic valve leaflet (clip mechanism) then subsequently leaving the coronary ostia freely accessible from heavily calcified aortic leaflet; 4) Meanwhile, J-Valve™ system has the advantage of achieving better anchoring through embrace the leaflets, then diminish the necessity of oversizing and minimize the risk of coronary obstruction.

Conclusion
The new J-Valve™ prosthesis is a brand new second generation TAVI device. This system may provide a safety treatment option for patient with high risk factor for coronary obstruction underwent TAVI procedure.

Acknowledgements
Not applicable.

Funding
None.

Availability of data and materials
The dataset of this case report is available from the corresponding author on reasonable request.

Authors’ contributions
HQ performed the statistical analysis and drafted the manuscript. YC participated in the surgery procedure and performed the CT scan. ZC participated in the design of the study and performed the statistical analysis. YG conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The hospital ethics committee approval was granted of this case report.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China. 2Department of Cardiology, West China hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China. 3Department of Cardiovascular Surgery, Heart Center of Henan Provincial Peoples Hospital and Fuwai central hospital, Zhengzhou, Henan, People’s Republic of China.

Received: 9 September 2018 Accepted: 17 February 2019

References
1. Ribeiro HB, Webb JG, Makkar RR, et al. Predictive factors, management, and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation: insights from a large multicenter registry. JACC Cardiovasc Interw. 2013;6:452–61.
2. Ribeiro HB, Nombela-Franco L, Urena M, et al. Coronary obstruction following transcatheter aortic valve implantation: a systematic review. JACC Cardiovasc Interw. 2013;6:452–61.
3. Zhu D, Wei L, Cheung A, et al. Treatment of Pure Aortic Regurgitation Using a Second-Generation Transcatheter Aortic Valve Implantation System. J Am Coll Cardiol. 2016;67:2803–5.